S&P 500
5,970.81
+0.0%
+$0.44
DJI
42,427.74
-0.2%
-$91.90
NASDAQ
19,460.49
+0.3%
+$61.53
Bitcoin
104,867.00
-1.0%
-1,043.28
AAPL
$202.99
-0.1%
-$0.28
AMZN
$207.37
+0.8%
+$1.66
GOOG
$169.50
+1.1%
+$1.79
META
$687.21
+3.1%
+$20.36
MSFT
$464.20
+0.3%
+$1.23
NVDA
$141.94
+0.5%
+$0.72
TSLA
$333.21
-3.2%
-$11.06
Landos Biopharma (NASDAQ: LABP)
Some price data may be temporarily unavailable.
Landos Biopharma Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Landos Biopharma Company Info
Landos Biopharma, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development of novel, oral, once-daily therapeutics for patients with certain immunology diseases. It offers NX-13, a novel, oral, gut-restricted compound for the treatment of inflammatory bowel disease, which targets the NLRX1 pathway. The firm's preclinical candidates include LABP-73, LABP-66, and LABP-69. The company was founded by Josep Bassaganya-Riera in January 2017 and is headquartered in Blacksburg, VA.
News & Analysis
No articles found.
Valuation
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.